{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:05:03Z","timestamp":1789643103919,"version":"4.0.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaad.2026.05.034","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:24:45Z","timestamp":1778945085000},"page":"979-987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel stratification framework based on vascular-fibrotic complications identifies distinct risk endotypes in systemic sclerosis: A retrospective cohort study"],"prefix":"10.1016","volume":"95","author":[{"given":"Huidan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.05.034_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2026.05.034_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.05.034_bib3","article-title":"Digital ulcers and microvascular abnormalities presenting as the initial manifestations of pre-scleroderma","volume":"16","author":"Arango","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jaad.2026.05.034_bib4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/biom15060772","article-title":"Molecular pathogenesis of connective tissue disease-associated pulmonary arterial hypertension: a narrative review","volume":"15","author":"Yeh","year":"2025","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.jaad.2026.05.034_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12016-022-08945-x","article-title":"Renal disease and systemic sclerosis: an update on scleroderma renal crisis","volume":"64","author":"Cole","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2026.05.034_bib6","first-page":"874","article-title":"Guidelines for the diagnosis and treatment of systemic sclerosis","volume":"61","author":"Zou","year":"2022","journal-title":"Chin J Intern Med"},{"issue":"7","key":"10.1016\/j.jaad.2026.05.034_bib7","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/jcm9072136","article-title":"Neutrophil extracellular traps generation relates with early stage and vascular complications in systemic sclerosis","volume":"9","author":"Didier","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jaad.2026.05.034_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2017.11.020","article-title":"Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature","volume":"17","author":"Giuggioli","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jaad.2026.05.034_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jaad.2026.05.034_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.jaad.2026.05.034_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"Jaafar","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.jaad.2026.05.034_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ard.2025.01.014","article-title":"Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database","volume":"84","author":"Yan","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2026.05.034_bib13","article-title":"Stratification according to autoantibody status in systemic sclerosis reveals distinct molecular signatures","author":"Rouvi\u00e8re","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2026.05.034_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41746-025-01962-y","article-title":"Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR study","volume":"8","author":"Trottet","year":"2025","journal-title":"NPJ Digit Med"},{"issue":"7","key":"10.1016\/j.jaad.2026.05.034_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ard.2025.04.025","article-title":"Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosis","volume":"84","author":"Li","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jaad.2026.05.034_bib16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.jaad.2026.05.034_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00296-025-05919-y","article-title":"Endothelial function and vascular events in patients with limited cutaneous systemic sclerosis (EFVELSS): a prospective observational study","volume":"45","author":"Jud","year":"2025","journal-title":"Rheumatol Int"},{"issue":"9","key":"10.1016\/j.jaad.2026.05.034_bib18","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s10067-018-4148-5","article-title":"Vascular complications in systemic sclerosis: a prospective cohort study","volume":"37","author":"Mecoli","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.05.034_bib19","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/rheumatology\/keab850","article-title":"Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study","volume":"61","author":"Hughes","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jaad.2026.05.034_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/ard-2021-221926","article-title":"Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation","volume":"82","author":"Ayoglu","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2026.05.034_bib21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10067-024-06886-8","article-title":"Digital gangrene in systemic sclerosis patients: not only due to the microvascular disease","volume":"43","author":"Hui","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"25","key":"10.1016\/j.jaad.2026.05.034_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003931","article-title":"Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease","volume":"95","author":"Perosa","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jaad.2026.05.034_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/03009742.2021.1887927","article-title":"Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients","volume":"50","author":"Lee","year":"2021","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.05.034_bib24","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s10067-025-07433-9","article-title":"BAricitinib in patients with SystemIC Sclerosis (BASICS): a prospective, open-label, randomised trial","volume":"44","author":"Chen","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.05.034_bib25","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3390\/biomedicines13071771","article-title":"Systemic sclerosis: a key model of endothelial dysfunction","volume":"13","author":"Zaccone","year":"2025","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.jaad.2026.05.034_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/biomedicines10020318","article-title":"Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: why IL-6?","volume":"10","author":"Cardoneanu","year":"2022","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.jaad.2026.05.034_bib27","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaad.2026.05.034_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2407526","article-title":"Autoantibodies in systemic sclerosis overlap syndrome and their correlation with organ damage and survival","volume":"56","author":"Wang","year":"2024","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.jaad.2026.05.034_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-023-03141-4","article-title":"Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study","volume":"25","author":"Hamberg","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2026.05.034_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejim.2023.07.010","article-title":"Prevalence of anti-synthetase antibodies among systemic sclerosis patients","volume":"117","author":"Garra","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaad.2026.05.034_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152667","article-title":"The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - a systematic review of the literature","volume":"72","author":"Hoekstra","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2026.05.034_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152606","article-title":"Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: a systematic literature review and meta-analysis","volume":"70","author":"Binda","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2026.05.034_bib33","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1093\/rheumatology\/keaf407","article-title":"Unveiling the clinical spectrum of ACA-positive SSC-ILD: not as benign as expected","volume":"64","author":"Valera-Ribera","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaad.2026.05.034_bib34","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.41814","article-title":"Anticentromere antibody levels and isotypes and the development of systemic sclerosis","volume":"73","author":"Van Leeuwen","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.05.034_bib35","first-page":"126","article-title":"The role of inflammatory markers in assessment of disease activity in systemic sclerosis","volume":"36 Suppl 113","author":"Ross","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.05.034_bib36","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/RHU.0000000000002253","article-title":"Predictors of persistent disease activity and damage in systemic sclerosis: associations with mortality in a single-center cohort study","volume":"31","author":"Moccaldi","year":"2025","journal-title":"J Clin Rheumatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226026708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226026708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:58:56Z","timestamp":1789642736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226026708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0190962226026708"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.05.034","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel stratification framework based on vascular-fibrotic complications identifies distinct risk endotypes in systemic sclerosis: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}